hypereosinophilic syndrome
Showing 1 - 25 of 25
Hypereosinophilic Syndrome Trial in Worldwide (Benralizumab, Placebo)
Recruiting
- Hypereosinophilic Syndrome
- Benralizumab
- Placebo
-
La Jolla, California
- +45 more
Feb 2, 2023
Eosinophilic Myeloid Tumor, Hypereosinophilic Syndrome Trial run by the National Institute of Allergy and Infectious Diseases
Recruiting
- Eosinophilic Myeloid Neoplasm
- Hypereosinophilic Syndrome
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 25, 2023
BCR-JAK2 Fusion Protein Expression, Blasts 20 Percent or Less of Peripheral Blood White Cells, Blasts More Than 5 Percent of
Recruiting
- BCR-JAK2 Fusion Protein Expression
- +11 more
-
Palo Alto, California
- +3 more
Oct 5, 2022
Familial Hypereosinophilia: Natural History and Markers of
Recruiting
- Eosinophilia
- Hypereosinophilic Syndrome
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Apr 7, 2022
Eosinophilia, Hypereosinophilic Syndrome, Leukocyte Disorder Trial run by the NIAID (prednisone)
Completed
- Eosinophilia
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Jan 26, 2022
Chronic Myelomonocytic Leukemia, Chronic Myeloid Leukemia, Polycythemia Vera Trial in Houston (Imatinib Mesylate (Gleevec))
Completed
- Chronic Myelomonocytic Leukemia
- +4 more
- Imatinib Mesylate (Gleevec)
-
Houston, TexasUT MD Anderson Cancer Center
Dec 7, 2021
Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), Hypereosinophilic Syndrome Trial
Completed
- Chronic Myelogenous Leukemia
- +3 more
-
Duarte, California
- +100 more
Jun 8, 2021
Eosinophilia, Hypereosinophilic Syndrome Trial in Stanford (Gleevec)
Terminated
- Eosinophilia
- Hypereosinophilic Syndrome
-
Stanford, CaliforniaStanford University School of Medicine
May 5, 2021
Hypereosinophilia and Hypereosinophilic Syndromes
Recruiting
- Eosinophilia
- Hypereosinophilic Syndrome
- Biological sample
-
Lille, FranceHôpital Roger Salengro, CHU
Aug 25, 2020
Hypereosinophilic Syndrome Trial in Worldwide (Mepolizumab)
Completed
- Hypereosinophilic Syndrome
-
La Jolla, California
- +35 more
Jun 4, 2020
Hypereosinophilia, Hypereosinophilic Syndrome Trial in Worldwide (mepolizumab)
Completed
- Hypereosinophilia
- Hypereosinophilic Syndrome
-
San Diego, California
- +28 more
May 1, 2020
Hypereosinophilic Syndrome Trial in Worldwide (Mepolizumab 300 mg, Placebo matching mepolizumab, Active OCS capsules (5 mg
Completed
- Hypereosinophilic Syndrome
- Mepolizumab 300 mg
- +3 more
-
San Diego, California
- +42 more
Feb 7, 2020
Hypereosinophilic Syndrome Trial in Limoges (Scheduled exams and diagnosis)
Unknown status
- Hypereosinophilic Syndrome
- Scheduled exams and diagnosis
-
Limoges, FranceMédecine Interne A
Jun 4, 2019
Acute Myeloid Leukemia, MDS, Agnogenic Myeloid Metaplasia Trial in Houston (Dasatinib (BMS-354825))
Completed
- Acute Myeloid Leukemia
- +7 more
- Dasatinib (BMS-354825)
-
Houston, TexasThe University of Texas M.D. Anderson Cancer Center
May 2, 2019
Hypereosinophilic Syndrome Trial in Lille (biologie sample)
Completed
- Hypereosinophilic Syndrome
- biologie sample
-
Lille, Nord, FranceCHRU, Hôpital Claude Huriez
Feb 14, 2019
Hypereosinophilic Syndrome Trial run by the NIAID (Dexpramipexole)
Unknown status
- Hypereosinophilic Syndrome
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Dec 6, 2017
Hypereosinophilic Syndrome Trial in Worldwide (mepolizumab)
Terminated
- Hypereosinophilic Syndrome
-
San Diego, California
- +23 more
Jun 7, 2017
Hypereosinophilic Syndrome, Systemic Mastocytosis, Chronic Myelomonocytic Leukemia Trial in East Melbourne (imatinib mesylate)
Completed
- Hypereosinophilic Syndrome
- +3 more
- imatinib mesylate
-
East Melbourne, AustraliaNovartis Investigative Site
Feb 21, 2017
Hypereosinophilic Syndrome Trial in Leuven (imatinib mesylate)
Terminated
- Hypereosinophilic Syndrome
- imatinib mesylate
-
Leuven, BelgiumNovartis Investigative Site
Apr 29, 2012
Hypereosinophilic Syndrome Trial run by the NIAID (SCH55700)
Completed
- Hypereosinophilic Syndrome
-
Bethesda, MarylandNational Institute of Allergy and Infectious Diseases (NIAID)
Mar 3, 2008